Yingqiu Xie

Department
School of Sciences and Humanities, National Laboratory Astana, Laboratory of Biophotonics and imaging, Immunobiology Laboratory, Biology
Title
Assistant Professor
Office
7114
Email
yingqiu.xie@nu.edu.kz

Dr. Xie received the Ph.D. in Genetics from Institute of Genetics and Developmental Biology, Chinese Academy of Sciences. During Ph.D. studies, Dr. Xie discovered a strong promoter for bio-engineering from viral genome which was awarded a USA patent. During his postdoctoral training at University of Maryland School of Medicine, Wadsworth Center, New York State Department of Health, Meharry Medical College, USA, Dr. Xie discovered novel bio-markers of prostate cancer such as PIM-1L and nMET. In 2008, Dr. Xie was awarded a Full Professor honor of “ Mount Tai” in China. In 2015, Dr. Xie joined Nazarbayev University.  Dr. Xie has been invited as speaker in a number of international conferences. Dr. Xie has international collaborations with well-established labs in USA, and has organized student international internships. Dr. Xie has supervised postgraduate and undergraduate students to carry out cancer research and published their research results or to pass their thesis defense. Dr. Xie’s current research is focusing on molecular and biochemical mechanisms of cancer progression, signaling networks, drug targets, Nano-medicine, Nano-genomics, Gene editing, bio-engineering, clinical urological oncology and precision cancer therapeutics. Dr. Xie has many publications of original research, review, or expert opinion in top journals such as Cancer Cell, European Urology, Oncogene, JBC,  and Cancer Research

EDUCATION

1999 – Ph.D.,  Institute of Genetics and Developmental Biology, Chinese Academy of Sciences

RESEARCH INTERESTS  

Gene editing; Nanomedicine and nanogenomics; Signaling networks and drug target in lung cancer, prostate cancer, breast cancer and leukemia; Anti-cancer drug resistance and stem cells; Aging in cancer; Environmental health; Oncology.

Patent (inventor, not the owner):

Zhu Zhen, Xie Yingqiu, Liu Yule. CLCuV Promoter and Its Use. United States Patent Number: 6,610,907, Aug 26, 2003 (approved and awarded)

Key Publications:  (Google scholar total citations:  1172)

  1. Xie Yingqiu, Filchakovaa Olena,  Qing Yang, Yerkebulan Yesbolatov, Darkhan Tursynkhan, Aishabibi Kassymbekb, Mohamed Bouhrara, Kunjie Wang, Mannix Balanay,  Haiyan Fan. Inhibition of Cancer Cell Proliferation by Carbon Dots Derived from Date Pits at Low-Dose. Chemistry Select, 2, 4079 – 4083, 2017 (SCI index)
  2. Xie Yingqiu*, Aidana Mustafa, Adina Yerzhan, Dalmira Merzhakupova, Perizat Yerlan, Askarbek Orakov,  et al. Nuclear Matrix Metalloproteinases: Functions Resemble the Evolution from the Intracellular to the Extracellular Compartment. Cell Death Discovery, 2017, Aug 14;3:17036. doi: 10.1038/cddiscovery.2017.36. eCollection 2017. https://www.nature.com/cddiscovery/ (corresponding author)
  3. Wenfu Lu, Shenji Liu, Bo Li, Xie Yingqiu, Michael G. Izban, Billy R. Ballard, Sandeep Anantha Sathyanarayana, Samuel E. Adunyah, Robert J. Matusik, and Zhenbang Chen. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer. Oncogene, 36 (10), 1364-1373, 2017. (SCI, IF 7.932)
  4. Wanjala Jackie, Barry Taylor, Caren Chapinski, Haley Hieronymus, John Wongvipat, Yu Chen, Gouri J Nanjangud, Nikolaus Schultz, Xie Yingqiu, Shenji Liu, Wenfu Lu, Qing Yang, Chris Sander, Chen Zhenbang, Sawyers L Charles, and Carver Brett S, Identifying Actionable Targets through Integrative Analyses of GEM Model and Human Prostate Cancer Genomic Profiling. Molecular Cancer Therapeutics, 14(1), 278-88. 2015  ( IF 5.863)
  5. Xie Yingqiu, Lu Wenfu, Liu Shenji, Yang Qing, Williams Kieosha, Carver Brett S, Matusik Robert J, and Chen Zhenbang. Slug regulates E-cadherin repression via p19Arf in prostate tumorigenesis. Molecular Oncology, 8(7), 1355-1364, 2014  
  6. Xie Yingqiu, Liu Shenji, Lu Wenfu, Yang Qing, Carver Brett S, Li Estelle, Wang Yuzhuo, Fazli Ladan, Gleave Martin and Chen Zhenbang. Crosstalk between Nuclear MET and SOX9/β-Catenin Correlates with Castration Resistant Prostate Cancer. Molecular Endocrinology, 28(10),1629-1639, 2014.  
  7. Natarajan Karthika, Xie Yingqiu, Burcu Mehmet, Linn Douglas, Qiu Yun, Baer Maria. Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication. PLoS One. Sep 5;8(9), e74653, 2013.
  8. Lu Wenfu, Xie Yingqiu, Ma Yu, Matusik Robert J, Chen Zhenbang. ARF represses androgen receptor transactivation in prostate cancer. Molecular Endocrinology, 27(4), 635-648, 2013.
  9. Linn Douglas, Yang Xi, Xie Yingqiu, Alfano Alan, Deshmukh Dhanraj, Wang Xin, Shimelis Hermela, Chen Hegang, Li Wei, Xu Kexin, Chen Mingyuan and Qiu Yun. Differential regulation of androgen receptor by PIM-1 kinases via phosphorylation-dependent recruitment of distinct ubiquitin E3 ligases. Journal of Biological Chemistry, 287(27), 22959-22968, 2012. 
  10. Xie Yingqiu, Burcu Mehmet, Linn Douglas, Qiu Yun, Baer Maria. Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression. Molecular Pharmacology, 78(2), 310-318, 2010.
  11. Xie Yingqiu, Xu Kexin, Linn Douglas, Guo Zhiyong, Hermela Shimelis Nakanishi Takeo, Ross Douglas D., Chen Hegang, Fazli Ladan, Gleave Martin E. and Qiu Yun. The 44 kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug resistant activity in human prostate cancer cells. Journal of Biological Chemistry, 283, 3349-3356, 2008.
  12. Xie Yingqiu, Xu Kexin, Dai Bojie, Guo Zhiyong, Jiang Tianyun, Chen hegang and Qiu Yun. The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs. Oncogene, 25, 70-78, 2006.
  13. Guo Zhiyong, Dai Bojie, Jiang Tianyun, Xu Kexin, Xie Yingqiu, Kim Oekyung et al. and Qiu Yun. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell, 10, 309-319, 2006.
  14. Dai Bojie, Kim Oekyung, Xie Yingqiu, Guo Zhiyong, Xu Kexin, Bin Wang, Xiangtian Kong, Melamed Jonathan, Chen Hegang, Bieberich Charles J., Borowsky Alexander D., Kung Hsing-Jien, Wei Guo, Ostrowski Michael C., Brodie Angela, and Qiu Yun. Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse. Cancer Research. 66, 8058-8064, 2006.
  15. Kim Oekyung, Jiang Tianyun, Xie Yingqiu, Guo Zhiyong, Chen hegang, Qiu Yun. Synergism of cytoplasmic kinases in IL-6-induced ligand-independent activation of androgen receptor in prostate cancer cells. Oncogene, 23, 1838-1844, 2004.
  16. Xie Yingqiu, Liu Yule, Meng Meng, Chen Lei, Zhu Zhen. Isolation and identification of a super strong plant promoter from cotton leaf curl Multan virus. Plant Molecular Biology, 53(1-2), 1-14, 2003.
  17. Xie Yingqiu, Madelian Vergine, Zhang Jianhua, Ling Guoyu, Ding Xinxin. Activation of the NPTA element of the rat CYP2A3 gene by NF1-A2, a nasal mucosa-selective nuclear factor I isoform. Biochemical and Biophysical Research Communications, 289(5), 1225-1228, 2001.